Catalog Number : 500-P140
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hCNTF. Anti-Human CNTF specific antibody was purified by affinity chromatography employing immobilized hCNTF matrix.
|Application:||ELISA, Western Blot, Neutralization, Immunohistochemistry|
Anti-Human CNTF (BioGems Catalog #450-13)
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.25 µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Optimal results for these conditions were achieved without antigen retrieval. Optimal concentrations and conditions may vary.
To yield one-half maximal inhibition [ND50] of the biological activity of Human CNTF (1.0 μg/ml) a concentration of 7.0 - 11.0 μg/ml of this antibody is required.
To detect hCNTF by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human CNTF (60-105BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hCNTF.
To detect hCNTF by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hCNTF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.